1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow ALN-6400: new trials by email Literature Review of ALN-6400 trials Research Report on ALN-6400
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB ALN-6400 - Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB) | Phase 2 | Recruiting | Alnylam Pharmaceuticals | 24 | 2026-07-30 | 2026-10-26 |
| A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) ALN-6400, Placebo - Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Active not recruiting | Alnylam Pharmaceuticals | 89 | 2024-11-07 | 2026-10-15 |
Epistaxis (1) · Menorrhagia (1) · Telangiectasia, Hereditary Hemorrhagic (1) · von Willebrand Diseases (1)
United States (2) · Australia (1) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · Spain (1) · Sweden (1) · Turkey (Türkiye) (1) · United Kingdom (1)
2025 (2)